Correlation between Trabecular Bone Score and Homocysteine Level in Rheumatoid Arthritis Patients on Anti-TNF Inhibitors
2024; Multidisciplinary Digital Publishing Institute; Volume: 14; Issue: 4 Linguagem: Inglês
10.3390/life14040463
ISSN2075-1729
AutoresFlorentina Ioniţă‐Radu, Iulia-Nadine Nicolau, Oana-Georgiana Petrache, Maria-Laura Groșeanu, Violeta‐Claudia Bojincă, Maria-Magdalena Negru, Săndica Bucurică, Daniela Anghel,
Tópico(s)Spondyloarthritis Studies and Treatments
ResumoRheumatoid arthritis (RA) is an independent osteoporosis risk factor. Biologic and immunosuppressive treatment, and levels of homocysteine and 25-OH vitamin D may influence the trabecular bone score (TBS) in RA patients. We aimed to compare the effects of biological (b) and conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) on TBS in patients with RA and hyperhomocysteinemia (HHcy) or 25-OH vitamin D deficiency. Patients who had tests conducted for trabecular bone score, bone mineral density (BMD), homocysteine (Hcy) and 25-OH vitamin D at an interval of one year and met the inclusion criteria were enrolled in this retrospective study. Sixty-four patients with RA were enrolled and were divided into the following two groups: the first group (34 patients) had received treatment with bDMARDs and the second group (30 patients) had received csDMARDs. BDMARDs and csDMARDs had a positive influence on TBS and BMD. The best results were observed in the Adalimumab group (
Referência(s)